TRDA Earnings & Financial Statements
Entrada Therapeutics, Inc.
$5.58
+$0.04(+0.81%)
37
Overall
60
Value
18
Tech
34
Quality
Market Cap
$215.32M
Volume
34.19K
52W Range
$5.17 - $16.45
Target Price
$17.00
TRDA earnings and financial statements: Entrada Therapeutics, Inc.'s income statement, balance sheet and cash flow statement, annual and quarterly.
TRDA Annual Financial Statements
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | $25.42M | $210.78M | $129.01M | - | - |
| Operating income | -$157.90M | $47.01M | -$3.16M | -$97.25M | -$51.13M |
| EBITDA | -$138.75M | $70.30M | $14.86M | -$95.35M | -$50.06M |
| Net income | -$143.75M | $65.63M | -$6.68M | -$94.62M | -$51.16M |
| EPS (diluted) | $-3.47 | $1.68 | $-0.20 | $-3.02 | $-8.16 |
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Total assets | $377.38M | $526.32M | $469.19M | $252.06M | $305.83M |
| Total liabilities | $71.25M | $97.64M | $226.83M | $39.50M | $7.12M |
| Shareholders’ equity | $306.13M | $428.68M | $242.36M | $212.55M | $298.72M |
| Cash and equivalents | $90.39M | $101.21M | $67.60M | $45.16M | $291.06M |
| Long-term debt | $46.79M | $51.65M | $60.32M | $17.53M | - |
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Operating cash flow | -$128.51M | -$41.56M | $139.80M | -$93.79M | -$50.86M |
| Capital expenditure | -$1.04M | -$3.16M | -$5.61M | -$2.89M | -$4.58M |
| Free cash flow | -$129.55M | -$44.72M | $134.19M | -$96.67M | -$55.44M |
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Vol |
| 2 | TRDA | $5.58 | +0.8% | 34.19K |
| 3 | ||||
| 4 | ||||
| 5 | ||||
| 6 |
Get Entrada Therapeutics, Inc. Data in Excel
Stream real-time data directly to your spreadsheets
BUY NOW